Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Fig. 2

Kaplan-Meier curves for TTF (a), PFS (b), and OS (c) in ISMT with paclitaxel, bevacizumab, and eribulin, ISMT, induction therapy followed by switch maintenance therapy; TTF, time to treatment failure, PFS, progression-free survival, and OS, overall survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us